Analyzing Aclaris Therapeutics (NASDAQ:ACRS) & I-Mab (NASDAQ:IMAB)

I-Mab (NASDAQ:IMAB) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Insider and Institutional Ownership

38.4% of I-Mab shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 22.1% of I-Mab shares are owned by insiders. Comparatively, 6.4% of Aclaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares I-Mab and Aclaris Therapeutics’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$27.64 million	3.10	-$206.44 million	N/A	N/A
Aclaris Therapeutics	$31.12 million	2.66	-$88.48 million	($1.09)	-1.06

Aclaris Therapeutics has higher revenue and earnings than I-Mab.

Profitability

This table compares I-Mab and Aclaris Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Aclaris Therapeutics	-248.28%	-61.03%	-46.97%

Analyst Ratings

This is a summary of current recommendations and price targets for I-Mab and Aclaris Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	0	0	4	0	3.00
Aclaris Therapeutics	0	6	1	0	2.14

I-Mab presently has a consensus price target of $12.25, suggesting a potential upside of 1,055.66%. Aclaris Therapeutics has a consensus price target of $22.25, suggesting a potential upside of 1,818.10%. Given Aclaris Therapeutics’ higher probable upside, analysts clearly believe Aclaris Therapeutics is more favorable than I-Mab.

Volatility & Risk

I-Mab has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500.

Summary

I-Mab beats Aclaris Therapeutics on 8 of the 12 factors compared between the two stocks.

About I-Mab

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.